argenx SE (A1RG34) - Cash Flow Conversion Efficiency
Based on the latest financial reports, argenx SE (A1RG34) has a cash flow conversion efficiency ratio of 0.059x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (R$361.85 Million) by net assets (R$6.10 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
argenx SE - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how argenx SE's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
argenx SE Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of argenx SE ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Discover Financial Services
NYSE:DFS
|
0.112x |
|
Petroleo Brasileiro S.A.
MC:XPBRA
|
0.123x |
|
Itau Unibanco Banco Holding SA
NYSE:ITUB
|
0.211x |
|
MetLife Inc
NYSE:MET
|
0.140x |
|
Ferrovial SE
NASDAQ:FER
|
0.024x |
|
NAURA Technology Group Co Ltd
SHE:002371
|
0.015x |
|
BOC Hong Kong (Holdings) Limited
F:BOF
|
-0.202x |
|
Cardinal Health Inc
NYSE:CAH
|
-0.254x |
Annual Cash Flow Conversion Efficiency for argenx SE (2021–2025)
The table below shows the annual cash flow conversion efficiency of argenx SE from 2021 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | R$7.32 Billion | R$685.19 Million | 0.094x | +721.72% |
| 2024-12-31 | R$5.50 Billion | R$-82.75 Million | -0.015x | +85.33% |
| 2023-12-31 | R$4.10 Billion | R$-420.33 Million | -0.103x | +66.55% |
| 2022-12-31 | R$2.81 Billion | R$-862.81 Million | -0.307x | -28.06% |
| 2021-12-31 | R$2.53 Billion | R$-606.81 Million | -0.239x | -- |
About argenx SE
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develo… Read more